It was recently announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) designated nintedanib, an oral triple angiokinase inhibitor by Boehringer Ingelheim,…
1717 K Street NW, Suite 900
Washington, DC 20006-5349
(877) 363-6376
HELPLINE
